ClinVar Miner

Submissions for variant NM_004380.3(CREBBP):c.3832G>A (p.Glu1278Lys) (rs267606752)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Genetic Services Laboratory, University of Chicago RCV000010040 SCV000192864 pathogenic Rubinstein-Taybi syndrome 1 2013-02-08 criteria provided, single submitter clinical testing
GeneDx RCV000255660 SCV000321525 pathogenic not provided 2018-01-10 criteria provided, single submitter clinical testing The E1278K missense variant in the CREBBP gene has been reported previously in association with Rubinstein-Taybi syndrome (Kalkhoven et al., 2003; Schorry et al., 2008). The E1278K variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. E1278K is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a conserved position within the plant homeodomain-type zinc finger region of the HAT domain (Kalkhoven et al., 2002). While functional studies involving the E1278 residue are conflicting (Kalkhoven et al., 2003; Rack et al., 2014), in silico analysis predicts this variant is probably damaging to the protein structure/function. Missense variants in the same residue (E1278A/G) have also been reported in the Human Gene Mutation Database in association with Rubinstein-Taybi syndrome (Stenson et al., 2014), supporting the functional importance of this region of the protein.
Wessex Regional Genetics Laboratory,Salisbury District Hospital RCV000010040 SCV000999449 likely pathogenic Rubinstein-Taybi syndrome 1 2019-11-05 criteria provided, single submitter clinical testing
Diagnostic Laboratory, Strasbourg University Hospital RCV001260694 SCV001437786 pathogenic Intellectual disability 2020-09-10 criteria provided, single submitter clinical testing
Ambry Genetics RCV001267080 SCV001445261 pathogenic Inborn genetic diseases 2019-09-09 criteria provided, single submitter clinical testing
Baylor Genetics RCV000010040 SCV001523211 pathogenic Rubinstein-Taybi syndrome 1 2020-08-19 criteria provided, single submitter clinical testing This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].
OMIM RCV000010040 SCV000030261 pathogenic Rubinstein-Taybi syndrome 1 2003-02-15 no assertion criteria provided literature only
Human Genetics - Radboudumc,Radboudumc RCV000255660 SCV001951579 likely pathogenic not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.